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BACKGROUND: To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer
(NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target rash (TR)); to
characterise the pharmacokinetics (PK) and pharmacodynamics (PD) of higher doses of erlotinib.
METHODS: Patients initially received erlotinib 150mg per day. The dose was successively increased in each patient to that associated
with a TR. Anticancer activity was evaluated. Plasma, skin, and hair were sampled for PK and PD studies.
RESULTS: Erlotinib dose escalation to 200–475mg per day was feasible in 38 (90%) of 42 patients. Twenty-four (57%) patients
developed a TR, but 19 (79%) did so at 150mg per day. Five (12%) patients, all of whom developed a TR, had a partial response.
Median progression-free survival (PFS) was 2.3 months (95% CI: 1.61, 4.14); median PFS was 3.5 months and 1.9 months,
respectively, for patients who did and did not experience a TR (hazard ratio, 0.51; P¼ 0.051). Neither rash severity nor response
correlated with erlotinib exposure.
CONCLUSION: Intrapatient dose escalation of erlotinib does not appreciably increase the propensity to experience a maximal level of
tolerable skin toxicity, or appear to increase the anticancer activity of erlotinib in NSCLC.
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Skin rash is the principal toxicity of both small molecule and
antibody therapeutics targeting the epidermal growth factor
receptor (EGFR), and retrospective analyses of a wide variety of
studies have suggested that skin toxicity correlates with clinical
benefit (Cohen et al, 2003; Perez-Soler et al, 2004; Saltz et al, 2004;
Shepherd et al, 2005; Gibson et al, 2006; Jonker et al, 2007; Van
Cutsem, 2007; Van Cutsem et al, 2007; Wacker et al, 2007). In the
BR21 placebo-controlled phase III trial of erlotinib (Tarceva, OSI
Pharmaceuticals Inc., Melville, NY, USA) in previously treated
patients with non-small cell lung cancer (NSCLC), for example, the
median survival for erlotinib-treated patients who did not
experience skin toxicity was 3 months compared with 7 and 11
months for those with grade 1 or grade 2/3 skin toxicity,
respectively (Wacker et al, 2007). Similar relationships have
been observed in other clinical trials of erlotinib and other
EGFR-targeting therapeutics, in a variety of malignancies
(Soulieres et al, 2004; Gordon et al, 2005; Herbst et al, 2005;
Berlin et al, 2007; Moore et al, 2007; Perez-Soler and Van Cutsem,
2007; O’Byrne et al, 2009; Verslype et al, 2009).
Since most patients with advanced NSCLC who are treated with
erlotinib at its recommended dose of 150mg per day do not
experience dose-limiting skin toxicity (Hidalgo et al, 2001), it was
reasoned that increasing the dose of erlotinib to that associated
with maximal level of tolerable skin toxicity (i.e., a target rash
(TR)) might increase the likelihood of observing anticancer
activity. The present trial was designed to assess the feasibility of
intrapatient erlotinib dose escalation to achieve a maximal level of
tolerable skin toxicity and to evaluate the anticancer activity,
pharmacokinetics (PK), and pharmacodynamic (PD) markers
associated with erlotinib treatment at these increased doses.
MATERIALS AND METHODS
Patients
Patient eligibility included an age of at least 18 years, a confirmed
diagnosis of stage 3B or 4 NSCLC, measurable disease, and
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treatment with at least one prior chemotherapy regimen in the
advanced setting. Other relevant eligibility criteria included: a life
expectancy of at least 12 weeks; Eastern Cooperative Group
performance status of 0 or 1; and adequate haematopoietic,
hepatic, and renal function. Patients with symptomatic or
progressive central nervous system metastases, prior treatment
with EGFR inhibitors; clinically relevant ophthalmologic abnorm-
alities; and/or known hypersensitivity to the tetracyclines were
excluded. The institutional review board/ethics committee of the
participating institutions approved the study protocol and patients
were required to give informed written consent.
Trial design
The study was conducted according to an open-label, modified Simon
two-stage design (Simon, 1989). In the initial stage, we assessed the
feasibility of intrapatient dose escalation from 150mg per day to a
maximal level of tolerable skin toxicity, which was defined as the TR.
This objective was determined to be feasible if patients developed a
TR in the absence of non-cutaneous dose-limiting toxicity (DLT). If
intrapatient dose escalation was feasible in at least five of the initial 15
patients, up to 31 additional patients were to be enrolled in the
second stage of the study. Skin toxicity was graded according to the
following scale that was based on patient tolerability:
 Grade 1 – a tolerable rash that did not require any symptomatic
treatment.
 Grade 2 – a tolerable rash that required symptomatic treatment
with minocycline, also defined as the TR.
 Grade 3 – an intolerable rash despite treatment with mino-
cycline as specified in the following section; or a symptomatic
rash associated with any of the following: opioid analgesics for
pain and/or systemic corticosteroids for pruritus; desquama-
tion/exfoliation of at least 25% of total body surface area; and/or
generalised urticaria.
The starting dose for all patients was erlotinib 150mg orally once
daily for 21 days. In the absence of both a TR and non-cutaneous
DLT, the dose was increased in each patient to 200mg per day, and
then in 25mg per day increments every 14 days. Therefore,
erlotinib doses were titrated in individual patients to achieve a
grade 2 TR. Non-cutaneous DLT was defined as: grade 3 or 4 non-
haematological toxicity, except for suboptimally managed nausea,
vomiting, or diarrhea; grade 4 neutropenia lasting longer than
5 days; grade 3 or 4 neutropenia with fever; grade 3 or 4 infection;
or a platelet counto25 000 ml1. Toxicities were graded according
to the National Cancer Institute Common Toxicity Criteria (NCI
CTC), Version 2.0, except for skin toxicity.
Doses were reduced in 25mg per day decrements for toxicity.
The initial systemic intervention for symptomatic skin toxicity was
minocycline 100–150mg twice daily for at least 7 days, and the
initiation of treatment with minocycline for symptomatic rash was
at the discretion of the investigator. The use of minocycline
preemptively (i.e., to prevent the development of skin rash) was
not allowed. In patients treated with minocycline, the erlotinib
dose was not increased and could be held until the skin toxicity
was felt to be tolerable, at which time, the same erlotinib dose
could be resumed, and further dose escalation, as described
previously, could be considered. Other interventions for skin
toxicity, including short courses of topical corticosteroids, were at
the investigators’ discretion. Patients continued erlotinib until
disease progression, intolerable toxicity, or withdrawal of consent.
Antitumour activity
Tumour assessments were performed using the Response Evalua-
tion Criteria in Solid Tumours using computerised tomographic
scanning or magnetic resonance imaging pretreatment and every
6–8 weeks during treatment (Therasse et al, 2000).
Statistical analysis
Intrapatient dose escalation was considered feasible for patients
who developed a TR without non-cutaneous DLT. In previous
studies, B30% of the patients receiving erlotinib 150mg per day
developed NCI CTC grade 2 or 3 rash; therefore, the null and
alternative hypotheses were that the feasibility rate wasp30% and
X50%, respectively (Shepherd et al, 2005; Perez-Soler and Van
Cutsem, 2007; Van Cutsem et al, 2007). The optimal, modified two-
stage Simon design tested these hypotheses with 0.05 probability of
accepting a dose escalation strategy if the null hypothesis was true
and 0.80 probability of rejecting the strategy if the alternative
hypothesis was true. If dose escalation was feasible in at least five
of the initial 15 patients, an additional 31 patients (46 total
patients) were planned to be enrolled. The dose escalation strategy
was to be declared feasible if 18 patients developed a TR.
Although this pilot study was not designed to demonstrate a
statistically significant increase in antitumour activity compared
with previous studies, a sample of 50 patients was estimated to
provide a 70% power to detect an increase from 10% to 20% in
response rate at the 5% level of significance, or 79% power at the
10% level of significance.
PK assessments
Plasma samples were collected pretreatment, and 1, 2, 4, 6, 8, and
24 h on day 14 of cycle 1, as well as 14 days after any dose
escalation. Samples were prepared and concentrations of erlotinib
and its principal metabolite OSI-420 were measured by high-
performance liquid chromatography as previously described
(Hamilton et al, 2006). PK parameters were estimated by non-
compartmental methods (WinNonlin v.3.1, Pharsight Corp.,
Mountain View, CA, USA).
PD assessments
Tumour tissue Paraffin embedded tumour blocks obtained at
diagnosis and/or recurrence were collected for assessment of
expression of EGFR, phosphorylated-EGFR (p-EGFR), extracellular
signal-regulated kinase (ERK), and phosphorylated-ERK (p-ERK)
using validated methods (EGFR PharmDX kit: Dako, Carpinteria,
CA, USA). The study was performed before the significance of
EGFR mutation status was fully appreciated and it was retro-
spectively concluded that the informed consent documents did not
encompass patient approval for this assay.
Skin biopsy samples Skin from affected and unaffected regions was
biopsied pretreatment and following the first appearance of a TR.
Other PD assessments Sebum and hair follicle samples were
obtained for exploratory analyses, and results will be presented
separately.
RESULTS
Patients
Forty-two patients, whose relevant demographic characteristics are
shown in Table 1, were enrolled between 2003 and 2005. Of note,
40 (95%) were either current or former smokers. All patients were
evaluable for toxicity and anticancer activity.
Erlotinib dose escalation and skin toxicity
During the first stage of the study, 10 of the 11 initial patients
enrolled developed a TR, and therefore 31 additional patients were
enrolled in the second stage of the study. Overall, 41 (98%) patients
developed skin toxicity and 24 (57%) developed a TR, which
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exceeded the predefined 50% requirement for declaring the dose
escalation scheme feasible. Nineteen (79%) patients developed a
TR at the initial 150mg per day dose level, whereas three (13%)
and two (8%) patients developed a TR following escalation to 200
and 225mg per day, respectively. Erlotinib doses were further
escalated in 21 (88%) of the 24 patients who developed a TR.
Six patients experienced a grade 3 rash, which resulted in the
reduction of doses to those associated with a TR. No patient was
discontinued from the study due to skin toxicity. One patient did
not develop a rash, and 16 patients never developed skin toxicity of
sufficient severity to be considered a TR before the development of
progressive disease.
Among the 38 (91%) patients in whom erlotinib doses were
increased, 32 (76%) patients achieved a final dose exceeding
150mg per day; doses were increased to 200mg per day in 17
patients, 225–350mg per day in 14 patients, and 475mg per day in
a single patient (Table 2). Four patients experienced early clinical
disease progression and discontinued the study before developing TR.
Anticancer activity
Five (12%; 95% CI: 4.0–25.6) patients had a PR, which was
achieved at a median maximal dose of 225mg per day (range,
125–275mg per day) (Table 3). The median duration of response
was 11 months (range, 4 to 46þ ). The median time to initial
response was 6 weeks (range, 5–76). The final daily dose among
these patients ranged from 100 to 275mg. All patients who
experienced a PR had either grade 1 (three patients) or grade 2
(two patients) skin toxicity at the initial erlotinib dose and all
achieved a TR during the study. Four of the responders were
males; three were Caucasian, and two were Hispanic. All
responders had non-squamous histology and were former
smokers. EGFR immunostaining was positive in three responders,
negative in one, with the last having an unknown status. Nineteen
(45%) patients experienced stable disease (13 lasting at least 3
months), 10 of whom experienced a TR, as did 9 of 18 patients who
had a best response of progressive disease.
The median progression-free survival (PFS) was 2.3 months
(95% CI: 1.61–4.14) for all patients. PFS values were 12 months
(range, 5.2 to 66þ ), 4.7 months (range, 1.2–14.0), and 1.4 months
(range, 1.2–1.9) for patients who experienced a PR, SD, and
progressive disease as their best response, respectively. The
median PFS values for individuals who did and did not experience
a TR were 3.5 months (95% CI: 1.61, 6.97) and 1.9 months (95% CI:
1.54, 4.14), respectively. There was a 49% reduction in the risk of
disease progression or death in patients who had TR (hazard ratio,
0.51%; 95% CI: 0.25–1.02; P¼ 0.051).
Toxicity
Toxicities as a function of dose are displayed in Table 4. The
principal toxicity of erlotinib in this study was skin rash,
predominately involving the face, neck, and upper torso and
characterised as erythemateous, maculopapular, acneiform, and/or
pustular. In 12 (29%) patients, the rash resembled rosacea, whereas
urticaria and desquamation were the dominant features in 11
(26%) and 16 (38%) patients, respectively. Symptoms associated
with skin toxicity, which were generally mild to modest in severity,
included pruritus in 28 (67%) patients and pain in 10 (24%)
patients. Medication to ameliorate symptoms were administered to
32 (76%) of patients. The use of minocycline and topical
corticosteroids was documented in 60% and 38% of patients,
respectively.
Seven patients experienced non-cutaneous DLT, all of whom
required dose reduction and symptomatic treatment. These dose-
limiting events included grade 3 fatigue (three patients), as well as
grade 3 headache, grade 3 creatinine elevation, grade 3 paronychia,
and grade 3 anorexia (one patient each). One patient discontinued
treatment due to protracted grade 3 anorexia and grade 2 nausea.
The most common toxicities included nausea (52% of patients),
vomiting (36%), diarrhea (79%), and stomatitis (33%), but these
events were well managed with routine supportive measures.
Fatigue and paronychia were also noted in 40% and 26% of the
patients, respectively. The frequency, but not the severity of
diarrhea, nausea, fatigue, and anorexia, was greater in patients
treated at the higher erlotinib dose levels.
Dermatological evaluations
Skin biopsies at the time of first appearance of TR were performed
in 23 (54%) patients. The principal histopathological findings
included altered terminal differentiation of keratinocytes, distorted
pilosebaceous units in the interfollicular epidermis, and mono-
nuclear cell infiltration associated with follicular destruction. The
pathological findings will be reported separately.
Pharmacokinetics
Thirty-one (74%) of 42 patients had PK analysis at erlotinib doses
exceeding 150mg per day. PK samples were available at 200mg in
25 patients, 300mg in 5, 325 and 350mg in 2, and 375, 400, 425,
450 and 475mg in 1 patient each. The principal PK parameters for
erlotinib and OSI-420 as a function of erlotinib dose level are
Table 1 Patient characteristics (n¼ 42)
Characteristic Number (%)
Male/female (%) 14 (33%)/28 (67)
Age
Median (range), years 63 (41–78)
Race/ethnicity
Caucasian 34 (81)
Hispanic 5 (12)
African-American 2 (5)
Asian 1 (2)
ECOG performance status
0 11 (26)
1 30 (71)
2 1 (2)
No. of prior chemotherapy regimens
1 19 (45)
2 13 (31)
42 10 (24)
Smoking status
Never smokers 2 (5)
Past history of smoking 35 (83)
Current smokers 5 (12)
Histologic subtype
Adenocarcinoma 23 (56)
Squamous cell carcinoma 11 (26)
Undifferentiated large cell 4 (10)
Mixed histology 2 (5)
Other 2 (5)
EGFR IHC at diagnosis (410% staining)
Positive 29 (68)
Negative 5 (12)
Unknown 8 (20)
Abbreviations: ECOG¼ Eastern Cooperative Oncology Group; EGFR¼ epidermal
growth factor receptor; IHC¼ immunohistochemistry.
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summarised in Table 5. High interpatient and intrapatient
variability for both erlotinib and OSI-420 was observed. A
Spearman rank correlation analysis of the relationships between
dose and both AUC0–24 and Cmax (across the dose range with
sufficient number of observations, 150–300mg) did not reveal any
significant deviation from dose proportionality; however, the
interpretation of such analyses is limited by the high intrapatient
variability and the small number of patients at higher dose levels.
Mean erlotinib plasma concentration–time profiles at the highest
dose attained are illustrated in Figure 1.
No significant relationships between erlotinib exposure and
relevant patient characteristics were observed. The single excep-
tion was smoking status, in which the erlotinib AUC0–24 was
significantly lower in smokers compared with former or never
Table 2 Erlotinib dose escalation
Maximum dose level Final dose level
Dose level Number of patients Median days of treatment (range) Number of patients Median days of treatment (range)
100 — — 2 (5%) 81 (21–140)
125 — — 2 (5%) 84 (14–153)
150 4 (10%) 22 (12–49) 6 (14%) 63 (42–119)
175 — — 2 (5%) 120 (30–210)
200 13 (31%) 14 (2–18) 15 (36%) 15 (2–342)
225 9 (21.5%) 14 (8–27) 5 (12%) 14 (8–14)
250 7 (17%) 8 (5–50) 4 (10%) 14 (5–50)
275 1 (2%) 26 2 (5%) 322 (26–618)
300 5 (12%) 51 (9–93) 2 (5%) 65 (51–78)
350 1 (2%) 14 1 (2%) 14
425 1 (2%) 1
475 1 (2%) 41 1 (2%) 41
Table 3 Antitumour activity as a function of target rash
Objective responses (CR+PR) Disease control (CR+PR+SD)
Patient
population
No. of patients with
PR+CR/total
no. of patients
Response rate
(95% CI)
Fisher’s exact
test P-value
No. of patients with
CR+PR+s.d./total no.
of patients
Response rate
(95% CI)
Fisher’s exact
test P-value
All patients 5/42 11.9 (4.0, 25.6) 24/42 57.1 (41.0, 72.3)
Target rash feasible 5/24 20.8 (7.1, 42.2) 0.06 15/24 62.5 (40.6, 81.2) 0.53
Target rash not feasible 0/18 0.0 (N/A) 9/18 50.0 (26.0, 74.0)
Abbreviations: CR¼ complete response; CI¼ confidence interval; PR¼ partial response; SD¼ stable disease; N/A¼ not applicable.
Table 4 Erlotinib-related toxicities (worst grade per patient) as a function of dose
Erlotinib dose
100–150mg (N¼ 4) 175–200mg (N¼ 13) 225–275mg (N¼ 18) X300mg (N¼ 7) Total (N¼ 42)
Grade Grade Grade Grade Grade
Any 3–4 Any 3–4 Any 3–4 Any 3–4 Any 3–4
Toxicity n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Diarrhea 4 (100) 0 (0) 9 (69) 0 (0) 13 (72) 1 (6) 7 (100) 0 (0) 33 (79) 1 (2)
Nausea 3 (75) 0 (0) 5 (38) 0 (0) 9 (50) 0 (0) 5 (71) 0 (0) 22 (52) 0 (0)
Vomiting 2 (50) 0 (0) 5 (38) 0 (0) 5 (28) 0 (0) 3 (43) 0 (0) 15 (36) 0 (0)
Stomatitis 2 (50) 0 (0) 5 (38) 0 (0) 6 (33) 0 (0) 1 (14) 0 (0) 14 (33) 0 (0)
Fatigue 3 (75) 0 (0) 4 (31) 1 (8)a 6 (33) 2 (11)a 4 (57) 0 (0) 17 (40) 3 (7)
Alopecia 0 (0) 0 (0) 0 (0) 0 (0) 4 (22) 0 (0) 2 (29) 0 (0) 6 (14) 0 (0)
Skin fissures 1 (25) 0 (0) 0 (0) 0 (0) 2 (11) 1 (6) 2 (29) 0 (0) 5 (12) 1 (2)
Anorexia 2 (50) 0 (0) 0 (0) 0 (0) 6 (33) 1 (6)a 3 (43) 0 (0) 11 (26) 1 (2)
Paronychia 0 (0) 0 (0) 0 (0) 0 (0) 3 (17) 0 (0) 2 (29) 1 (14)a 5 (12) 1 (2)
Epistaxis 0 (0) 0 (0) 0 (0) 0 (0) 3 (17) 0 (0) 2 (29) 0 (0) 5 (12) 0 (0)
Headache 0 (0) 0 (0) 0 (0) 0 (0) 1 (6) 1 (6)a 0 (0) 0 (0) 1 (2) 1 (2)
Creatinine 0 (0) 0 (0) 1 (8) 1 (8)a 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 1 (2)
Abbreviation: N¼ number. aNon-cutaneous dose limiting toxicity reported.
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smokers (P-values 0.03 and 0.004, respectively); however, the
numbers of current and never smokers were small. Rash severity
did not relate to erlotinib exposure (determined after 14 days of
each escalation) nor did best response relate to PK parameters
(AUC0–24 and Cmax) reflecting exposure to erlotinib and OSI-420.
Pharmacodynamics
Among the 34 patients evaluable for EGFR expression on archival
tumour blocks, 29 (85%) had EGFR immunostaining in at least
10% of tumour cells. The intensity of EGFR immunostaining did
not relate to the achievement of a TR, response, nor PFS. Although
a trend towards reductions in phosphorylated-EGFR/EGFR protein
activity compared with pretreatment levels was seen in a larger
proportion in patients who developed the TR compared with
patients who did not, no definitive conclusions can be drawn
regarding these skin PD studies and the severity of rash and/or
response due to the small number of samples available (data not
shown).
DISCUSSION
This study demonstrated that the dose escalation of erlotinib above
its recommended dose of 150mg per day to a maximal level of
tolerable skin toxicity is feasible but does not seem to result in
increased antitumour activity in this patient population (Shepherd
et al, 2005; Ardavanis et al, 2008; Felip et al, 2008; Hesketh et al,
2008; Spiegel et al, 2008; Tiseo et al, 2009). Erlotinib doses could
not be increased above the dosing range of 250–300mg per day in
most patients, principally due to intolerable skin toxicity despite
various supportive measures, particularly treatment with minocy-
cline and topical corticosteroids. Although dose escalation of
erlotinib above 150mg per day was feasible, 19 (79%) of 24
patients who achieved a TR did so after a short period of treatment
at the initial erlotinib dose level of 150mg per day, and only five
(21%) of the patients who ultimately experienced a TR did so after
dose escalation. These findings suggest that further erlotinib dose
escalation above 150mg per day does not increase the propensity
of achieving a TR in most individuals who have the potential to do
so, and that 150mg per day is an adequate erlotinib dose if the
objective is to achieve a TR. In 22 patients, erlotinib doses were
increased above the dose that was initially associated with the
development of a TR. However, treatment at higher erlotinib dosesT
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was associated with a higher rate of mild-to-moderate fatigue,
diarrhea, nausea, vomiting, and stomatitis than reported for the
approved 150mg per day dose (Shepherd et al, 2005).
A notable increase in anticancer activity was not observed in this
unselected patient population. For example, median PFS and ORR
values were 2.2 months (95% CI: 1.9–2.9 months) and 8.9% (95%
CI: 6.4–12%), respectively, in the BR.21 study (Shepherd et al,
2005), compared with 2.3 months (95% CI: 1.61–4.14) and 12%
(95% CI: 4.0–25.6), in the present study. Although these results
suggest that the dose escalation approach used in this study is
unlikely to confer incremental activity in this patient population,
the existence of a dose–activity relationship, which may have been
demonstrated using alternate approaches such as treatment with
higher erlotinib doses from the outset, cannot be ruled out. The
dose escalation scheme in this study was conservative, and disease
progression was rapid in most patients, thereby precluding a
meaningful duration of treatment at higher doses in a sufficient
number of patients. However, all patients who achieved an
objective response experienced a TR and it is noteworthy that
the median time to objective response in these patients was
relatively brief. Furthermore, both the initial and final erlotinib
doses associated with these objective responses, as well as the TR,
were not much higher than the starting dose of 150mg per day.
These findings suggest that the propensity to experience an
objective response is more likely to be linked to factors inherent to
the individual patient and the tumour rather than dose and related
factors such as drug exposure. Finally, four patients in our study
underwent dose reduction to 125 or 100mg erlotinib after
developing intolerable rash at 150mg, and they continued on
treatment for a median of 84 days (range, 14–153). These findings,
together with the reports of efficacy of lower doses of erlotinib in
patients with known EGFR mutations suggest that, in the presence
of rash, dose reductions to ‘subtherapeutic’ levels remain effective
and may prevent unnecessary early treatment termination (Lind
et al, 2009).
The principal objective of the present study was to determine
the antitumour activity of erlotinib in previously treated NSCLC
patients by achieving maximal rash based on numerous retro-
spective analyses of clinical trial data (Cohen et al, 2003; Perez-
Soler et al, 2004; Saltz et al, 2004; Gibson et al, 2006; Berlin et al,
2007; Jonker et al, 2007; Perez-Soler and Van Cutsem, 2007; Van
Cutsem, 2007; Van Cutsem et al, 2007; Wacker et al, 2007).
The hypothesis was based on the notion that skin toxicity may
be a surrogate for the inhibition of EGFR TK phosphorylation in
the cancer itself. However, since it is now recognised that the most
robust tumour responses noted with EGFR inhibitors occur in
patients with activating EGFR mutations (Lynch et al, 2004), it is
not surprising that dose escalation of erlotinib to the maximal dose
associated with a TR did not result in an increased response rate in
this unselected patient population. Unfortunately, tumour tissue
was not assessed for EGFR mutation analysis due to the absence of
informed consent for mutational analyses as the trial was
conducted before significance of EGFR mutations were reported.
EGFR expression in tumour tissue in this trial was determined by
immunohistochemistry; however, the optimal biomarker for the
selection of patients with NSCLC for treatment with EGFR
inhibitors remains to be determined. Recent studies have
determined that the EGFR gene copy number (as determined by
FISH) in addition to the EGFR mutation status may also be
important predictors to response to small-molecule inhibitors of
EGFR (Hirsch et al, 2008). Nevertheless, it is possible, albeit
unlikely based on the results of the present study, that higher doses
of erlotinib may result in more potent inhibition of wild-type
EGFR, whose overexpression/activation may also play a role in the
pathogenesis of NSCLC (Fujimoto et al, 2005). Larger randomised
trials (i.e., 150mg per day as a fixed dose vs rapidly escalating
doses of erlotinib) in a selected population for the relevant target
and with adequate patient stratification (i.e., by gender, histology,
smoking history, EGFR amplification/mutation, etc.) would be
needed to rigorously address this hypothesis.
There were no relationships between erlotinib PK parameters
reflecting drug exposure and clinical activity in this study, which is
not surprising. Indeed, the large intrapatient variability of the
erlotinib PK observed in this and other studies, as well as the
relatively small size of the trial, may have contributed negatively,
in part, to this observation (Soulieres et al, 2004; Herbst et al, 2005;
Perez-Soler and Van Cutsem, 2007). The lack of relationships
between PK parameters of drug exposure with toxicity and clinical
activity also underscores the importance of tumour biology and host
features relative to dose and drug exposure in the development of
toxicity and clinical benefit in this disease setting. Similarly, no
relationship between the PK parameters of OSI-420, the main active
metabolite of erlotinib and clinical activity were observed.
In conclusion, intrapatient dose escalation of erlotinib above
150mg to achieve a TR was feasible, but most patients who
developed TR did so at the initial dose and this dose escalation
scheme did not result in increased anticancer activity in previously
treated, unselected NSCLC patients compared with historical data
in patients treated with a standard dosing regimen. In addition,
treatment with erlotinib at higher doses resulted in increased non-
cutaneous toxicities, which may have negatively impacted on the
quality of life in some patients. Therefore, dose escalation of
erlotinib above the approved dose of 150mg is not recommended
for use in this disease setting.
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